Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Non-cash Items (2022 - 2026)

Sagimet Biosciences' Non-cash Items history spans 5 years, with the latest figure at $4.0 million for Q1 2026.

  • Quarterly Non-cash Items rose 45.83% to $4.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Mar 2026, up 45.83% year-over-year, with the annual reading at $3.8 million for FY2025, 50.69% up from the prior year.
  • Non-cash Items came in at $4.0 million for Q1 2026, up from $3.8 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $10.3 million in Q2 2024 to a low of $8000.0 in Q4 2023.
  • The 5-year median for Non-cash Items is $3.1 million (2025), against an average of $3.6 million.
  • Year-over-year, Non-cash Items tumbled 99.8% in 2023 and then skyrocketed 7637.5% in 2024.
  • Sagimet Biosciences' Non-cash Items stood at $4.0 million in 2022, then crashed by 99.8% to $8000.0 in 2023, then surged by 7637.5% to $619000.0 in 2024, then soared by 513.73% to $3.8 million in 2025, then grew by 5.23% to $4.0 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Non-cash Items are $4.0 million (Q1 2026), $3.8 million (Q4 2025), and $3.4 million (Q3 2025).